FINWIRES · TerminalLIVE
FINWIRES

Gilead Sciences Faces Long-Term Questions on Yeztugo Growth, RBC Capital Markets Says

By

Gilead Sciences (GILD) is seeing strong pre-exposure prophylaxis growth, although questions remain on long-term Yeztugo growth, with expectations for the drug potentially having "gotten ahead of themselves," RBC Capital Markets said in a note Thursday.

The brokerage said regional use patterns in existing PrEP markets underscore the challenges Gilead may face in substantially expanding overall PrEP use over the long term, while persistence for Yeztugo "seems not to be as good as initially hoped."

The HIV business remains solid, driven by strong US Descovy sales in Q1, and the company's $400 million increase to full-year sales guidance reflects confidence in the continued growth of the business, according to the note.

RBC maintained a sector perform rating on the stock and lowered its price target to $122 from $123.

Shares of Gilead Sciences were down 2.5% in Friday trading.

Price: $130.71, Change: $-3.35, Percent Change: -2.50%

Related Articles

Wire

ESCO Technologies Fiscal Q2 Adjusted Earnings, Revenue Rise; Shares Fall After Hours

ESCO Technologies (ESE) reported fiscal Q2 adjusted earnings late Thursday of $1.91 per diluted share, up from $1.17 a year earlier.Three analysts polled by FactSet expected $1.84.Net sales in the three months ended March 31 rose to $309.3 million from $231.8 million a year earlier.Three analysts surveyed by FactSet expected $307.9 million.ESCO boosted full-year adjusted EPS guidance to $8 to $8.25 from its February forecast of $7.90 to $8.15. The company maintained its revenue outlook of $1.29 billion to $1.33 billion.Three analysts surveyed by FactSet project EPS of $8.15 on revenue of $1.32 billion.The company kept its quarterly dividend at $0.08 per share, payable July 17 to stockholders of record July 2.ESCO shares fell 6.1% in after-hours trading.

$ESE
Wire

Gen Digital Fiscal Q4 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Gen Digital (GEN) reported fiscal Q4 adjusted earnings late Thursday of $0.67 per diluted share, up from $0.59 a year earlier.Analysts polled by FactSet expected $0.65.Revenue in the three months ended April 3 rose to $1.28 billion from $1.01 billion a year earlier.Analysts surveyed by FactSet expected $1.25 billion.Gen Digital expects Q1 EPS of $0.68 to $0.70 on revenue of $1.30 billion to $1.325 billion.Analysts polled by FactSet project EPS of $0.68 on revenue of $1.27 billion.The company expects fiscal 2027 EPS of $2.85 to $2.95 on revenue of $5.33 billion to $5.43 billion.Analysts surveyed by FactSet project EPS of $2.85 on revenue of $5.24 billion.Gen Digital shares jumped 9% in after-hours trading.

$GEN
Wire

JFrog Q1 Non-GAAP Earnings, Revenue Rise; Lifts 2026 Guidance

JFrog (FROG) reported Q1 non-GAAP earnings late Thursday of $0.27 per diluted share, up from $0.20 a year earlier.Analysts polled by FactSet expected $0.21.Revenue for the quarter ended March 31 was $154.0 million, up from $122.4 million a year earlier.Analysts surveyed by FactSet expected $147.4 million.For Q2, the company expects non-GAAP EPS of $0.23 to $0.25 on revenue of $154 million to $156 million. Analysts expect $0.21 and $151.7 million, respectively.For 2026, JFrog now expects non-GAAP EPS of $0.93 to $0.97 on revenue of $628 million to $632 million, up from the prior forecast of non-GAAP EPS of $0.88 to $0.92 on revenue of $623 million to $628 million.Analysts expect $0.90 and $627.7 million, respectively.Shares of JFrog rose 15% in after-hours activity.

$FROG